Madrigal Pharmaceuticals stock
Price history
−23.30% over the period1 year: from $553.42 (November 17, 2025) to $424.48 (November 17, 2026), −23.30%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $424.48 |
| October 30, 2026 | $430.36 |
| September 30, 2026 | $503.96 |
| August 31, 2026 | $540.03 |
| July 31, 2026 | $467.32 |
| June 30, 2026 | $536.95 |
| May 29, 2026 | $497.27 |
| April 30, 2026 | $517.39 |
| March 31, 2026 | $523.47 |
| February 27, 2026 | $432.00 |
| January 30, 2026 | $489.31 |
| December 31, 2025 | $582.34 |
| November 28, 2025 | $596.98 |
| November 17, 2025 | $553.42 |
At a glance
The company
Biopharmaceutical company developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH)
Latest results
Quarter to June 30, 2026 · EPS -$1.99 (estimate -$2.75)
TickerLandia's take on Madrigal Pharmaceuticals
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−31.38% from the 52-week high
Analysts · 19 analysts
Average target$688.78+63.22% vs. price
Buy 18 · Hold 1 · Sell 0 · Strong buy
TickerLandia Fingerprint: Madrigal Pharmaceuticals
Compared with similar companies: very weak momentum.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricehigh65
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 6.95 36 Forward P/E 38.1 72 Price/book 15.8 85 Profitabilitylow32
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 91.0% 73 ROE −24.8% 12 ROA −6.8% 22 Operating margin −10.7% 29 Net margin −10.9% 22 Growthhigh73
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +50.10% 80 Earnings growth (year over year) +31.90% 65 Financial strengthlow25
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −13.5 10 Debt/equitycounts in reverse: lower means more financial strength 0.56 21 Current ratio 3.05 45 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery weak16
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −19.89% 13 Distance from 200-day average −14.47% 17 Relative strength (3 months) −14.00% 20 Relative strength (6 months) −20.68% 15 Riskaverage51
How much the price swings.
Metric Value Position in group Volatility (60 days) 34.9% 52 Beta (1 year) 0.44 38 Maximum drawdown (12 months) 34.3% 63
1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Madrigal Pharmaceuticals is pricier than similar companies
Madrigal Pharmaceuticals's Forward P/E: 38.1, +136% against the median of a group of 7 similar companies (16.1).
Compared with 7 similar companies
| Metric | Madrigal Pharmaceuticals | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 38.1 | High | |
| Operating margin | -10.7% | Middle | |
| ROE | -24.8% | Low | |
| Debt/equity | 0.56 | Middle | |
| Price/book | 15.8 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Madrigal Pharmaceuticals. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$364.25M
Latest quarter · Q2 2026
Net income
-$57.94M
Latest quarter · Q2 2026
Quarterly net margin
-15.9%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $9.93B
- EPS
- -$5.85
- Volume
- 441.25K
- Daily trading
- €223.02M
- Dividend yield
- 0.00%
How Madrigal Pharmaceuticals is changing
All resultsShares outstanding up 45.2% in 5 years
Profitable in 0 of 5 fiscal years
Returns
Madrigal Pharmaceuticals returns
$1,000 invested in Madrigal Pharmaceuticals 5 years ago, on November 17, 2021, would be worth $4,881 today: +388.13% in total, +37.32% per year. This is the price return only: dividends are excluded.
| Period | Madrigal Pharmaceuticals | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −5.06% | −3.17% | $949 |
| 6 months | −19.42% | +0.11% | $806 |
| Year to date | −27.11% | +8.34% | $729 |
| 1 year | −23.30% | +11.15% | $767 |
| 3 years | +140.28% | +64.30% | $2,403 |
| 5 years | +388.13% | +58.18% | $4,881 |
| 10 years | +2,449.43% | +239.10% | $25,494 |
Over the last 6 months it has done better than 9% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Madrigal Pharmaceuticals: technical analysis
Madrigal Pharmaceuticals is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 30.0% below its all-time closing high ($602.83, December 22, 2025).
- Trend
- Downward
- RSI (14 sessions)
- 40
- Between 30 and 70
- vs 200-session average
- −14.81%
Support and resistance
Price areas where Madrigal Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$487.41+15.50%4 touches, last on November 3, 2026
- Resistance$461.62+9.39%3 touches, last on June 11, 2026
- Resistance$446.11+5.71%2 touches, last on July 30, 2026
- Last price$421.99
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.44
- Volatility (60 sessions, annualised)
- 34.9%
- Largest fall in the last year
- −34.26%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Madrigal Pharmaceuticals: seasonality
Average monthly price change over 20 years
Over the last 20 years, the strongest month for Madrigal Pharmaceuticals has been December: +23.10% on average, positive in 10 years out of 19. The weakest has been June: −4.74% on average, positive in 9 years out of 20. November, the current month, has been positive in 12 years out of 19 (+6.41% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.42% | −0.69% | 9 of 19 |
| February | −0.68% | +2.05% | 12 of 19 |
| March | −0.92% | −4.03% | 7 of 20 |
| April | +7.53% | +0.90% | 11 of 20 |
| May | +4.59% | −5.02% | 7 of 20 |
| June | −4.74% | −1.32% | 9 of 20 |
| July | +0.41% | −4.80% | 6 of 20 |
| August | +2.92% | −1.98% | 10 of 20 |
| September | +6.46% | −5.13% | 9 of 20 |
| October | −1.60% | −2.11% | 9 of 20 |
| November | +6.41% | +6.38% | 12 of 19 |
| December | +23.10% | +2.45% | 10 of 19 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Madrigal Pharmaceuticals and its competitors
Madrigal Pharmaceuticals, Inc. recorded revenue of $958.4 million in the fiscal year ended December 2025, and its work is concentrated on metabolic dysfunction-associated steatohepatitis, or MASH, a form of liver disease. The biopharmaceutical company develops novel therapeutics for this condition, with a focus on the United States market. Its main product is Rezdiffra, a liver-directed thyroid hormone receptor beta agonist used for treating MASH, which is the basis of its commercial activity.
- Headquarters
- West Conshohocken, United States
- Employees
- 915
- Founded
- 2011
- Chief executive
- William Sibold
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Madrigal PharmaceuticalsMDGL | $9.93B | -10.7% | — | −19.42% |
| Corcept TherapeuticsCORT | $9.36B | 0.8% | 190.2 | +24.30% |
| BioMarin PharmaceuticalBMRN | $11.09B | 16.3% | 146.8 | +12.93% |
| Summit TherapeuticsSMMT | $11.32B | 0.0% | — | −36.75% |
| Bio-TechneTECH | $11.43B | 21.7% | 66.8 | +67.74% |
| Twist BioscienceTWST | $7.4B | -28.8% | — | +127.78% |
Same industry or related industries, similar size. Compare Madrigal Pharmaceuticals with its competitors · Full profile
